Trial Profile
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- 14 Feb 2024 Status changed from active, no longer recruiting to completed.
- 16 May 2022 Planned End Date changed from 29 Oct 2023 to 29 Dec 2023.
- 05 Jan 2022 Planned End Date changed from 14 Dec 2021 to 29 Oct 2023.